High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Balance Sheet: Strong Balance Sheet.
Insider Trading: There's significant insider buying recently.
Profitability: Very strong Profitability. One year profit margin are 17%.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Declining Revenues! Trailing 12m revenue has fallen by -16.7% in past one year. In past three years, revenues have changed by -3.3%.
Technicals: SharesGuru indicator is Bearish.
Momentum: Stock is suffering a negative price momentum. Stock is down -8.8% in last 30 days.
Past Returns: Underperforming stock! In past three years, the stock has provided -12.1% return compared to 7.7% by NIFTY 50.
Valuation | |
|---|---|
| Market Cap | 37.43 kCr |
| Price/Earnings (Trailing) | 32.12 |
| Price/Sales (Trailing) | 5.5 |
| EV/EBITDA | 19.27 |
| Price/Free Cashflow | -58.14 |
| MarketCap/EBT | 24.86 |
| Enterprise Value | 37.38 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 6.8 kCr |
| Rev. Growth (Yr) | -11.1% |
| Earnings (TTM) | 1.17 kCr |
| Earnings Growth (Yr) | -39% |
Profitability | |
|---|---|
| Operating Margin | 21% |
| EBT Margin | 22% |
| Return on Equity | 10.37% |
| Return on Assets | 8.67% |
| Free Cashflow Yield | -1.72% |
Growth & Returns | |
|---|---|
| Price Change 1W | -0.60% |
| Price Change 1M | -8.8% |
| Price Change 6M | -20.9% |
| Price Change 1Y | -34.9% |
| 3Y Cumulative Return | -12.1% |
| 5Y Cumulative Return | -5% |
| 7Y Cumulative Return | 12.2% |
| 10Y Cumulative Return | 11.9% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -613.5 Cr |
| Cash Flow from Operations (TTM) | 474 Cr |
| Cash Flow from Financing (TTM) | -171 Cr |
| Cash & Equivalents | 283.3 Cr |
| Free Cash Flow (TTM) | -643.8 Cr |
| Free Cash Flow/Share (TTM) | -42.43 |
Balance Sheet | |
|---|---|
| Total Assets | 13.44 kCr |
| Total Liabilities | 2.21 kCr |
| Shareholder Equity | 11.23 kCr |
| Current Assets | 7.49 kCr |
| Current Liabilities | 1.78 kCr |
| Net PPE | 3.68 kCr |
| Inventory | 1.22 kCr |
| Goodwill | 602.8 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.02 |
| Debt/Equity | 0.02 |
| Interest Coverage | 72.81 |
| Interest/Cashflow Ops | 24.24 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 15 |
| Dividend Yield | 0.61% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Balance Sheet: Strong Balance Sheet.
Insider Trading: There's significant insider buying recently.
Profitability: Very strong Profitability. One year profit margin are 17%.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Declining Revenues! Trailing 12m revenue has fallen by -16.7% in past one year. In past three years, revenues have changed by -3.3%.
Technicals: SharesGuru indicator is Bearish.
Momentum: Stock is suffering a negative price momentum. Stock is down -8.8% in last 30 days.
Past Returns: Underperforming stock! In past three years, the stock has provided -12.1% return compared to 7.7% by NIFTY 50.
Investor Care | |
|---|---|
| Dividend Yield | 0.61% |
| Dividend/Share (TTM) | 15 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 76.8 |
Financial Health | |
|---|---|
| Current Ratio | 4.22 |
| Debt/Equity | 0.02 |
Technical Indicators | |
|---|---|
| RSI (14d) | 20.73 |
| RSI (5d) | 51.8 |
| RSI (21d) | 35.34 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Buy |
| SharesGuru Signal | Buy |
| RSI Signal | Buy |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
Summary of PI Industries's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Management provided an optimistic outlook for FY27, expecting to achieve growth supported by improved performances in exports and the global biologicals sector. Consolidated revenue for FY26 stood at Rs.67,137 million with an EBITDA margin of 25%. The company anticipates that exports and new product launches, particularly in agro and pharma, will drive growth momentum.
Key forward-looking points from management included:
Overall, management emphasized a robust strategy focused on innovation, product differentiation, and resilience amidst industry challenges.
Question: What is the significance of the INR 2,600 crore capex incurred over the past three years, and what impact is it expected to have on revenue? Answer: The capex investments are aimed at multi-year ramp-ups in capacity and technology, which have longer gestation periods. We are seeing some returns from these investments in the upcoming year and behind newer business arenas, which require more time to mature.
Question: How is growth expected for the FY26 CSM business, excluding the largest agro CSM product? Answer: New molecules currently contribute around 18% to the total portfolio, and while overall revenue faced challenges, they are showing promising growth rates, with expectations to improve further in the coming periods.
Question: Can we anticipate further reductions in contract assets, which are currently at INR 700 crore? Answer: The reduction reflects better utilization, and we expect contract assets to remain within the same range due to underlying business models and structures, despite being subject to fluctuations depending on market conditions.
Question: What is the company's outlook for margins moving into FY27? Answer: We're targeting continued management of average gross margins at the previous year's level. However, due to market volatility, providing specific future margins will depend on various factors, including input costs.
Question: What is the market potential for the newly launched biological nematode product? Answer: The unique foliar application-based nematode product is expected to see significant growth, especially in Brazil and Mexico, with sales potentially tripling this year. The global market is expanding as farmers recognize nematode problems.
Question: What are the revenue expectations for the pharma segment and timelines for achieving EBITDA positivity? Answer: We expect to generate INR 500 crore to INR 600 crore in revenue in the pharma segment, but achieving EBITDA positivity could take another couple of years based on developing capabilities and customer confidence.
Question: How is the electronic chemicals segment expected to grow? Answer: We anticipate investments could reach around INR 500 crore in electronic chemicals over the coming years. Our projection targets about $100 million in revenue from this segment over the next 4-5 years, indicating the potential for significant growth as we develop new products.
These detailed questions and answers encapsulate the strategic outlook and financial expectations for PI Industries as discussed in their earnings conference call.
Analysis of PI Industries's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Jun 30, 2026
| Description | Share | Value |
|---|---|---|
| Agro Chemicals | 96.8% | 1.6 kCr |
| Pharma | 3.2% | 54.2 Cr |
| Total | 1.7 kCr |
Understand PI Industries ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| MAYANK SINGHAL | 20.45% |
| MADHU SINGHAL | 9.42% |
| ICICI PRUDENTIAL MANUFACTURING FUND | 7.61% |
| LICI NEW PENSION PLUS GROWTH FUND | 7.01% |
| POOJA SINGHAL JOINTLY WITH SHEFALI KHUSHALANI(Trustees of Beta Family Trust) | 4.05% |
| POOJA SINGHAL JOINTLY WITH SHEFALI KHUSHALANI(Trustees of Alpha Family Trust) | 4.05% |
| SHEFALI KHUSHALANI JOINTLY WITH MADHU SINGHAL(Trustees of Domane Family Trust) | 4.05% |
| SHEFALI KHUSHALANI JOINTLY WITH MADHU SINGHAL(Trustees of Rcane Family Trust) | 4.05% |
| KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK NIFTY COMM | 2.58% |
| SBI ARBITRAGE OPPORTUNITIES FUND | 2.24% |
| MIRAE ASSET NIFTY LARGEMIDCAP 250 INDEX FUND | 1.97% |
| AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL F | 1.9% |
| TATA NIFTY MIDCAP 150 INDEX FUND | 1.04% |
| SALIL SINGHAL | 0% |
| POOJA SINGHAL | 0% |
| SALIL SINGHAL (Trustee in SVVK Family Benefit Trust) | 0% |
| SHEFALI KHUSHALANI | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of PI Industries against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| UPL | UPL | 48.8 kCr | 53.54 kCr | -3.60% | -20.00% | 23.96 | 0.91 | - | - |
| SUMICHEM | SUMITOMO CHEMICAL INDIA | 26.21 kCr | 3.4 kCr | -0.60% | -7.90% | 45.22 | 7.71 | - | - |
| BAYERCROP | Bayer CropScience | 19.83 kCr | 5.71 kCr | -3.60% | -23.70% | 28.39 | 3.18 | - | - |
| DHANUKA | Dhanuka Agritech | 4.39 kCr | 2 kCr | -2.90% | -38.80% | 16.57 | 2.2 | - | - |
| RALLIS | Rallis India | 4.16 kCr | 3 kCr | -6.80% | -42.20% | 19.5 | 1.38 | - | - |
Comprehensive comparison against sector averages
PIIND metrics compared to Fertilizers
| Category | PIIND | Fertilizers |
|---|---|---|
| PE | 32.8 | 26.6 |
| PS | 5.62 | 1.82 |
| Growth | -16.7 % | 7.7 % |
PI Industries is a prominent player in the Pesticides & Agrochemicals sector, with the stock ticker PIIND. The company boasts a robust market capitalization of Rs. 55,364.9 Crores.
Based in Gurugram, India, PI Industries Limited specializes in the manufacture and distribution of agrochemicals not just within India, but also across Asia, North America, Europe, and other international markets. Their product offerings include a variety of agrochemicals such as insecticides, herbicides, fungicides, and bio stimulants. These products are designed for crop protection and nutrition, addressing issues related to weeds, insects, and diseases across a wide range of crops, including rice, cotton, tomato, chili, potato, onion, grapes, pomegranate, and apples.
In addition to product manufacturing, PI Industries invests heavily in research and development (R&D). Their R&D services encompass target discovery, molecule design, and biological evaluation among other advanced analytic and synthesis processes. They also provide custom synthesis and manufacturing solutions, ensuring comprehensive support for their clients through various stages of product development.
The company operates through an extensive distribution network, selling products via distributors, dealers, and retailers. Historically known as Mewar Oil & General Mills Ltd., PI Industries was incorporated in 1946.
With a trailing 12 months revenue of Rs. 8,260.4 Crores and a profit of Rs. 1,699.2 Crores in the past year, PI Industries has demonstrated significant financial strength. Notably, the company has experienced 58% revenue growth over the last three years. It also rewards its investors with dividends, offering a dividend yield of 0.58% annually and distributing Rs. 21 per share in the last year.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
PIIND vs Fertilizers (2021 - 2026)